Skip to content

Study · Observational study · 2019

4 results

Post hoc analysis of the Exenatide-PD trial-Factors that predict response.

Athauda D, Maclagan K, Budnik N, Zampedri L, Hibbert S, Aviles-Olmos I, Chowdhury K, Skene SS, Limousin P, Foltynie T

The European journal of neuroscience6 Oct 2018Cited by 68 (Europe PMC)

PMID30070753 (opens in a new tab)DOI10.1111/ejn.14096 (opens in a new tab)PepBankPUB-30070753
Publisher pagePubMedAsk about this study
Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

4 results from studies that gave the peptide. 4 results from people.

  1. 01HumanObservational studyOther

    In Parkinson's disease, tremor-dominant phenotype predicted the greatest motor response to exenatide.

    In plain wordsIn Parkinson's disease, tremor-dominant phenotype was linked to the greatest motor response to exenatide.

    Peptide
    Exenatide (exendin-4)
    Outcome
    IncreaseMotor response by phenotype
    Study

    n: not reported in source

    Analysis
    Exploratory
    Outcome group
    Neuroprotection · Nervous system and cognition
    Studied dose
    Dose not stated

    Source sentences

    Summary
    however, tremor-dominant phenotype and lower Movement Disorder Society-Sponsored Revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Part-2 scores predicted greatest motor response to exenatide
    2 context sentences
    Summary · context
    Univariate and multivariate analyses were conducted to determine possible predictors of motor response to exenatide in this cohort.
    Summary · context
    Potential treatment by subgroup interactions for changes in; motor severity, nonmotor symptoms, cognition, and quality of life after 48-weeks treatment with exenatide
  2. 02HumanObservational studyOther

    In Parkinson's disease, lower MDS-UPDRS Part-2 scores predicted the greatest motor response to exenatide.

    In plain wordsIn Parkinson's disease, lower MDS-UPDRS Part-2 scores were linked to the greatest motor response to exenatide.

    Peptide
    Exenatide (exendin-4)
    Outcome
    IncreaseMotor response by baseline MDS-UPDRS Part-2
    Study

    n: not reported in source

    Analysis
    Exploratory
    Outcome group
    Neuroprotection · Nervous system and cognition
    Studied dose
    Dose not stated

    Source sentences

    Summary
    however, tremor-dominant phenotype and lower Movement Disorder Society-Sponsored Revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Part-2 scores predicted greatest motor response to exenatide
    2 context sentences
    Summary · context
    Univariate and multivariate analyses were conducted to determine possible predictors of motor response to exenatide in this cohort.
    Summary · context
    Potential treatment by subgroup interactions for changes in; motor severity, nonmotor symptoms, cognition, and quality of life after 48-weeks treatment with exenatide
  3. 03HumanObservational studyOther

    In Parkinson's disease, older age of onset was linked to a possibly poorer response to exenatide.

    In plain wordsIn Parkinson's disease, older age of onset was linked to a possibly poorer response to exenatide.

    Peptide
    Exenatide (exendin-4)
    Outcome
    DecreaseResponse by age at onset
    Study

    n: not reported in source

    Analysis
    Exploratory
    Outcome group
    Neuroprotection · Nervous system and cognition
    Studied dose
    Dose not stated

    Source sentences

    Summary
    and there was an indication that patients with older age of onset and disease duration over 10 years responded less well.
    2 context sentences
    Summary · context
    Univariate and multivariate analyses were conducted to determine possible predictors of motor response to exenatide in this cohort.
    Summary · context
    Potential treatment by subgroup interactions for changes in; motor severity, nonmotor symptoms, cognition, and quality of life after 48-weeks treatment with exenatide
  4. 04HumanObservational studyOther

    In Parkinson's disease, disease duration over 10 years was linked to a possibly poorer response to exenatide.

    In plain wordsIn Parkinson's disease, duration over 10 years was linked to a possibly poorer response to exenatide.

    Peptide
    Exenatide (exendin-4)
    Outcome
    DecreaseResponse by disease duration
    Study

    n: not reported in source

    Analysis
    Exploratory
    Outcome group
    Neuroprotection · Nervous system and cognition
    Studied dose
    Dose not stated

    Source sentences

    Summary
    and there was an indication that patients with older age of onset and disease duration over 10 years responded less well.
    2 context sentences
    Summary · context
    Univariate and multivariate analyses were conducted to determine possible predictors of motor response to exenatide in this cohort.
    Summary · context
    Potential treatment by subgroup interactions for changes in; motor severity, nonmotor symptoms, cognition, and quality of life after 48-weeks treatment with exenatide

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    22 Oct 2026, 02:26 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.